Pacific Biosciences Of California (PACB) Revenue (2010 - 2026)

Pacific Biosciences Of California's Revenue history runs 17 years deep, the most recent figure standing at $37.2 million for Q1 2026.

• On a quarterly basis, Revenue changed 0.07% year-over-year to $37.2 million in Q1 2026; TTM through Mar 2026 was $160.0 million, a 5.04% increase from a year earlier, with the FY2025 full-year figure at $160.0 million, up 3.89% from the prior year.
• Revenue declined to $37.2 million in Q1 2026 per PACB's latest filing, from $44.6 million in the prior quarter.
• Across five years, Revenue topped out at $58.4 million in Q4 2023 and bottomed at $27.4 million in Q4 2022.
• The 5-year median for Revenue is $38.8 million (2024), against an average of $40.0 million.
• Across the five-year window, Revenue surged 113.35% in 2023 and tumbled 32.79% in 2024, its largest moves.
• Year by year, Revenue stood at $27.4 million in 2022, then surged by 113.35% to $58.4 million in 2023, then tumbled by 32.79% to $39.2 million in 2024, then rose by 13.82% to $44.6 million in 2025, then dropped by 16.73% to $37.2 million in 2026.
• Per Business Quant, the three latest PACB Revenue figures stand at $37.2 million (Q1 2026), $44.6 million (Q4 2025), and $38.4 million (Q3 2025).